[Thienam (imipenem/cilastatin) as an agent for empirical antibiotic therapy].
The clinicobacteriological efficacy and tolerance of thienam (imipenem/cylastatin) were studied in the empirical therapy of 38 patients with severe purulent inflammatory diseases of various localization i.e. pneumonia, lung abscesses, pyothorax, peritonitis, abdominal abscesses, meningitis and brain abscesses. The treatment of all the patients with the drug was started before the data on the bacteriological investigation were available. Although the infections and the general state of the patients were extremely severe, the therapy with thienam proved to be efficient in 31 out of 35 cases (88.6 per cent) subjected to the drug efficacy estimation. The bacteriological diagnoses with respect to 24 out of 38 patients (64.7 per cent) were available later: 93.6 per cent of the isolates was sensitive to imipenem. The antimicrobial activity of imipenem against 254 clinical isolates assayed by the method of serial dilutions exceeded that of the majority of the currently used antimicrobial drugs, including aminoglycosides, 3rd generation cephalosporins and ureldopenicillins. The tolerance of thienam was good. Only in 4 out of 38 patients it was necessary to use some other drugs because of the side effects. Therefore, the use of the thienam is advisable as a drug of empirical monotherapy in patients with severe infections of the respiratory organs, abdominal cavity and central nervous system.